Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…Abstract Number: 0992 • ACR Convergence 2022
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Background/Purpose: Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that is active in multiple autoimmune disease models, including murine models of SLE and LN.…Abstract Number: 1117 • ACR Convergence 2022
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of Type I IFNs, IL-23, and IL-12, key cytokines involved in lupus pathogenesis. Deucravacitinib (DEUC) is an oral,…Abstract Number: 1282 • ACR Convergence 2022
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
Background/Purpose: Patients with autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN) and granulomatosis with polyangiitis (GPA) frequently require treatment with immunosuppressive drugs.…Abstract Number: 1380 • ACR Convergence 2022
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…Abstract Number: 1453 • ACR Convergence 2022
Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus
Background/Purpose: Muscle inflammation in systemic lupus erythematosus (SLE) usually presents as generalised myalgia in the presence of active disease elsewhere and responds well to treatment.…Abstract Number: 1473 • ACR Convergence 2022
Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical presentations. Patient-reported outcomes (PROs) can aid in the measurement of the burden of…Abstract Number: 1594 • ACR Convergence 2022
Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…Abstract Number: 1708 • ACR Convergence 2022
A Role for the RAGE Receptor in Chronic Neurotoxicity After Exposure to SLE Antibodies That Cross React with dsDNA and the NMDA Receptor
Background/Purpose: Neurologic dysfunction occurs in up to 80% of SLE patients. Cognitive impairment is one of the most frequent manifestations of neuropsychiatric SLE (NPSLE). There…Abstract Number: 1764 • ACR Convergence 2022
Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a complex and poorly understood etiology and is difficult to diagnose due to its varied presentation across many organ…Abstract Number: 2060 • ACR Convergence 2022
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
Background/Purpose: SLE disproportionately affects individuals of African (AA) compared to European ancestry (EA). In addition to a higher incidence, the disease is more severe in…Abstract Number: 2078 • ACR Convergence 2022
Mesangial Lupus Nephritis: Long Term Outcomes
Background/Purpose: Mesangial lupus nephritis (LN class II) is generally considered benign with minimal potential for developing advanced chronic kidney disease (CKD). However, a certain proportion…Abstract Number: 2098 • ACR Convergence 2022
Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
Background/Purpose: Lupus can present as either systemic lupus erythematous (SLE) and/or a cutaneous form known as cutaneous lupus erythematous (CLE). While a lot of data…Abstract Number: 2222 • ACR Convergence 2022
Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…Abstract Number: 0056 • ACR Convergence 2022
Pilot Study to Implement the Type 1 & 2 SLE Model in an Academic Rheumatology Clinic
Background/Purpose: The Type 1 & 2 SLE Model was developed to better explain the signs, symptoms, and management goals of SLE to patients. We assembled…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 150
- Next Page »